Personalizing CA125 levels for ovarian cancer screening

Cancer Prevention Research

Volumn 4, Issue 9, 2011, Pages 1356-1359

  Dorigo, Oliver ^a   Berek, Jonathan S ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; ORAL CONTRACEPTIVE AGENT;

ALGORITHM; CANCER SCREENING; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG UTILIZATION; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; HIGH RISK POPULATION; HUMAN; MENOPAUSE; NOTE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RISK OF OVARIAN CANCER ALGORITHM; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; CA-125 ANTIGEN; CONTRACEPTIVES, ORAL; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MASS SCREENING; MEDICAL ONCOLOGY; MENOPAUSE; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PROGNOSIS; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 80052558221     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0378     Document Type: Note

References (18)

1. Bast R.C., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-1337 (Pubitemid 12235035)
2. Yin B.W., Lloyd K.O. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J Biol Chem 2001;276:27371-27375
3. O'Brien T.J., Beard J.B., Underwood L.J., Dennis R.A., Santin A.D., York L. The CA 125 gene: And extracellular superstructure dominated by repeated sequences. Tumour Biol 2001;276:348-366 (Pubitemid 34062947)
4. Gubbels J.A., Belisle J., Onda M., Rancourt C., Migneault M., Ho M., et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006;5:50.
5. Patankar M.S., Jing Y., Morrison J.C., Belisle J.A., Lattanzio F.A., Deng Y., et al. Potent suppression of natural killer cell response mediated by ovarian tumor marker CA125. Gynecol Oncol 2005;99:704-713 (Pubitemid 41686556)
6. Davelaar E.M., Van Kamp G.J., Verstraeten R.A., Kenemans P. Comparison of seven immunoassays for the quantification of CA125 antigen in serum. Clin Chem 1998;44:1417-1422 (Pubitemid 28309100)
7. Kabawat S.E., Bast R.C. Jr, Bhan A.K., Welch W.R., Knapp R.C., Colvin R.B. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983;2:275-285 (Pubitemid 14176989)
8. Spitzer M., Kaushal N., Benjamin F. Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med 1998;43:387-392 (Pubitemid 28196441)
9. Bon G.G., Kenemans P., Verstraeten R., Van Kamp G.J., Hilgers J. Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values. Am J Obstet Gynecol 1996;174:107-114 (Pubitemid 26037697)
10. Pauler D.K., Menon U., McIntosh M., Symecko H.L., Skates S.J., Jacobs I.J. Factors influencing serum CA125 levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:489-493 (Pubitemid 32701635)
11. Skates S.J., Mai P., Horick N.K., Piedmonte M., Drescher C.W., Isaacs C., et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res 2011;4:1401-1408
12. Koenker R., Hallock K. Quantile regression: An introduction. J Economic Perspectives 2001;15:143-156
13. Jacobs I.J., Skates S., Davies A.P., Woolas R.P., Jeyerajah A., Weidemann P., et al. Risk of diagnosis of ovarian cancer after raised serum CA125 concentration: A prospective cohort study. BMJ 1996;313: 1355-1358 (Pubitemid 26400120)
14. Menon U., Gentry-Maharaj A., Hallett R., Ryan A., Burnell M., Sharma A., et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10: 327-340
15. Kobayashi H., Yamada Y., Sado T., Sakata M., Yoshida S., Kawaguchi R., et al. A randomized study of screening for ovarian cancer: A multicenter study in Japan. Int J Gynecol Cancer 2008;18:414-420 (Pubitemid 351668303)
16. Buys S.S., Partridge E., Black A., Johnson C.C., Lamerato L., Isaacs C., et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295-2303
17. Cramer D.W., Bast R.C. Jr, Berg C.D., Diamandis E.P., Godwin A.K., Hartge P., et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011;4:365-374
18. Zhu C.S., Pinsky P.F., Cramer D.W., Ransohoff D.F., Hartge P., Pfeiffer R.M., et al. A framework for evaluating biomarkers for early detection: Validation of biomarker panels for ovarian cancer. Cancer Prev Res 2011;4:375-383